Xencor (XNCR) Expected to Announce Quarterly Earnings on Thursday

Xencor (NASDAQ:XNCR) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Xencor to post earnings of ($0.64) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 9:30 AM ET.

Xencor Price Performance

Xencor stock opened at $11.34 on Thursday. The firm has a market capitalization of $809.79 million, a P/E ratio of -6.41 and a beta of 0.98. Xencor has a one year low of $6.92 and a one year high of $18.69. The business has a fifty day moving average price of $13.74 and a 200-day moving average price of $12.59.

Insiders Place Their Bets

In other Xencor news, CEO Bassil I. Dahiyat sold 114,377 shares of Xencor stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.71, for a total value of $1,796,862.67. Following the transaction, the chief executive officer directly owned 466,635 shares of the company’s stock, valued at $7,330,835.85. The trade was a 19.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president directly owned 236,574 shares in the company, valued at approximately $3,718,943.28. The trade was a 23.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. RTW Investments LP lifted its position in Xencor by 8.9% during the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after buying an additional 556,407 shares during the period. State Street Corp grew its position in shares of Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after buying an additional 833,423 shares during the period. Geode Capital Management LLC increased its stake in shares of Xencor by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 1,752,918 shares of the biopharmaceutical company’s stock worth $26,842,000 after acquiring an additional 24,093 shares in the last quarter. Legal & General Group Plc lifted its position in Xencor by 603.7% during the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after acquiring an additional 1,092,095 shares during the period. Finally, UBS Group AG boosted its stake in Xencor by 51.4% during the third quarter. UBS Group AG now owns 1,175,267 shares of the biopharmaceutical company’s stock worth $13,786,000 after acquiring an additional 399,071 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on XNCR. JPMorgan Chase & Co. reduced their target price on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Royal Bank Of Canada upped their target price on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Cantor Fitzgerald raised their price target on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Truist Financial assumed coverage on shares of Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 price target on the stock. Finally, Barclays increased their price objective on Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.88.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.